Related Experiment Video
Updated: Jul 23, 2025
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Are we ready for personalized CAR-T therapy?
Anna Strzelec1, Grzegorz Helbig1
1Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Abstract:
The future of chimeric antigen receptor T (CAR-T) therapy remains unclear. New studies are constantly being published confirming the efficacy and favorable safety profile of its innovative enhancements. Currently approved CAR-T drugs are manufactured exclusively for a specific patient from the recipient's own cells. This does not close the door to further modifications with subsequent personalization and better adaptation to the individual needs. Bringing such a drug to market would involve raising the already high costs, so it is necessary to lower the existing ones. On the other hand, so-called universal CAR-T are also getting closer to the patient's bed, but its implementation may struggle with multiple challenges, including development of graft-versus-host disease (GvHD) and alloimmunity. However, that off-the-shelf therapy could prove useful as a quick solution for patients in very poor condition or excluded from current therapy due to manufacturing limitations. The introduction of currently tested solutions may undoubtedly change the current paradigm of treatment.
Insights
Chimeric antigen receptor T (CAR-T) therapy innovations are advancing, with personalized treatments showing efficacy but high costs. Universal CAR-T offers potential but faces challenges like graft-versus-host disease.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Chimeric antigen receptor T (CAR-T) therapy is a rapidly evolving field.
- Current CAR-T therapies are autologous, manufactured individually for each patient.
- This personalized approach presents manufacturing limitations and high costs.
Purpose of the Study:
- To explore the future landscape of CAR-T therapy.
- To discuss advancements in personalized CAR-T and the emergence of universal CAR-T.
- To address the challenges and potential of these innovative treatments.
Main Methods:
- Review of current literature and ongoing research in CAR-T therapy.
- Analysis of efficacy and safety profiles of enhanced CAR-T treatments.
- Evaluation of the challenges associated with universal CAR-T development.
Main Results:
- New studies confirm the efficacy and safety of CAR-T therapy enhancements.
- Personalized CAR-T modifications offer better adaptation but increase costs.
- Universal CAR-T therapies are nearing clinical application but face hurdles like graft-versus-host disease (GvHD) and alloimmunity.
Conclusions:
- CAR-T therapy is undergoing significant innovation, balancing personalization with cost-effectiveness.
- Universal CAR-T presents a promising alternative for specific patient groups, despite implementation challenges.
- These advancements are poised to reshape the treatment paradigm in oncology.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
